This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
By This Author:
« Back
Page 1 of 346

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study

By Adam Feuerstein

The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.

09:40AM 03/27/15

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

By Adam Feuerstein

If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.

07:17AM 03/26/15

Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy

By Adam Feuerstein

In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.

10:06AM 03/25/15

PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company

By Adam Feuerstein

Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.

10:39AM 03/24/15

High Alert for Signs of Biotech Collapse Makes for Nervous Investors

By Adam Feuerstein

Biotech stocks may or may not be in a bubble, but investors are definitely worried about sky-high valuations.

08:56AM 03/24/15

Vertex Cystic-Fibrosis Drug Smacked by Burden of High Expectations

By Adam Feuerstein

Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.

09:07AM 03/23/15

Biogen, Alzheimer's and the Biotech Mania (Is It a Bubble?)

By Adam Feuerstein

Biogen shares are up on strong Alzheimer's drug data, but is the biotech bull market making investors forget about risk?

12:29PM 03/20/15

Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

07:18AM 03/20/15

Biogen's Alzheimer's Drug Exceeds (or Meets) Expectations, Depending on Your View

By Adam Feuerstein

Biogen Idec's drug BIIB037 slowed cognitive decline and reduced brain plaques in Alzheimer's patients.

06:40AM 03/20/15

Amicus Accelerates Approval Filing Plans for Rare Disease Drug

By Adam Feuerstein

Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.

07:41AM 03/19/15

« Back
Page 1 of 346

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs